Talaris investor relations
Web31 Dec 2024 · In 2024, we changed our corporate name from Regenerex, Inc. to Talaris Therapeutics, Inc. Since our inception, we have devoted substantially all of our resources … WebTalaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
Talaris investor relations
Did you know?
Web5847 San Felipe. Suite 3300. Houston, TX 77057. Phone: +1 713 789 1400. Investor Relations: Tim Richardson. Director – Investor Relations. [email protected]. Web30 Jun 2024 · In 2024, we changed our corporate name from Regenerex, Inc. to Talaris Therapeutics, Inc. Since our inception, we have devoted substantially all of our resources to developing our lead product candidate, FCR001, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for …
Web12 Apr 2024 · Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in nine FDA-approved medicines and numerous product candidates in a range of diseases, including blindness-causing eye diseases, severe inflammatory conditions like asthma and atopic dermatitis, hematologic conditions, pain and infectious … Web8 Nov 2024 · Talaris maintains corporate offices in Boston, MA, and its cell processing facility in Louisville, KY. For additional information, visit talaristx.com, and follow Talaris …
Web10 Nov 2024 · Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update. Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of … WebOfficer. 12/31/2024. Acquisition (Non Open Market) Direct. 1,470. $13.00. 451,236. Back to TALS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 …
Web12 Apr 2024 · 3 Wall Street analysts have issued 12-month target prices for Talaris Therapeutics' stock. Their TALS share price forecasts range from $3.00 to $23.00. On average, they expect the company's share price to reach $13.00 in the next year. This suggests a possible upside of 630.3% from the stock's current price.
Web11 Aug 2024 · Talaris Overview Founded Year2024 LocationBoston, United States Company StagePublic Total Funding$215M Last Funding Round$115M, Series B, Oct 06, 2024 Similar Cos.GigaGen, Orca Bio, Xenikos, Polyneuron, REGiMMUNE&11others Disclaimer: Total Funding = Total Disclosed Equity Funding (Pre-exit) property management companies high point ncWeb--Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe ... property management companies hurst txWebTalaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting BOSTON and LOUISVILLE, Ky., Oct. 17, 2024 (GLOBE … ladybird king of the hill wikiWebWe must receive your request at least two business days prior to the meeting at our principal executive offices at Talaris Therapeutics, Inc., 93 Worcester Street, Wellesley, MA 02481, … ladybird key words reading schemeWeb©2024 Talaris Therapeutics. All rights reserved. ladybird introductionWebThe Talaris team is composed of highly experienced leaders in the fields of immunology, cell therapy, clinical development, manufacturing, and people development. Scott Requadt … property management companies hot springs arWeb7 Mar 2024 · View Greg Tollerud's business profile as Customer Service - General at Goodin Company. Find contact's direct phone number, email address, work history, and more. property management companies in abbotsford